Barclays PLC Y M Abs Therapeutics, Inc. Transaction History

Barclays PLC

$288 Billion
Q1 2024

A detailed history of Barclays PLC transactions in Y M Abs Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 25,738 shares of YMAB stock, worth $311,429. This represents 0.0% of its overall portfolio holdings.

Number of Shares

25,738

Previous 50,437 48.97%

Holding current value

$311,429

Previous $344,000 21.51%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$6.57 - $18.69 $162,272 - $461,624	-24,699 Reduced 48.97%	25,738 $418,000
Q4 2023 Feb 15, 2024	BUY	$4.88 - $7.42 $215,378 - $327,481	44,135 Added 700.33%	50,437 $344,000
Q3 2023 Nov 07, 2023	SELL	$4.86 - $7.23 $4,932 - $7,338	-1,015 Reduced 13.87%	6,302 $34,000
Q2 2023 Aug 03, 2023	SELL	$5.68 - $10.34 $227,722 - $414,551	-40,092 Reduced 84.57%	7,317 $49,000
Q1 2023 May 04, 2023	BUY	$2.83 - $5.11 $106,266 - $191,880	37,550 Added 380.87%	47,409 $237,000

Q4 2022 Feb 13, 2023	SELL	$3.0 - $15.17 $163,758 - $828,069	-54,586 Reduced 84.7%	9,859 $48,000
Q3 2022 Nov 03, 2022	BUY	$13.96 - $19.67 $860,410 - $1.21 Million	61,634 Added 2192.6%	64,445 $929,000
Q2 2022 Aug 12, 2022	SELL	$8.22 - $15.13 $24,528 - $45,147	-2,984 Reduced 51.49%	2,811 $43,000
Q1 2022 May 16, 2022	SELL	$6.55 - $17.42 $354,898 - $943,867	-54,183 Reduced 90.34%	5,795 $68,000
Q4 2021 Feb 14, 2022	BUY	$15.51 - $29.31 $659,314 - $1.25 Million	42,509 Added 243.34%	59,978 $972,000
Q3 2021 Nov 09, 2021	BUY	$27.47 - $37.31 $291,594 - $396,045	10,615 Added 154.87%	17,469 $498,000
Q2 2021 Aug 13, 2021	SELL	$25.45 - $37.64 $690,891 - $1.02 Million	-27,147 Reduced 79.84%	6,854 $232,000
Q1 2021 May 13, 2021	BUY	$29.16 - $51.96 $637,350 - $1.14 Million	21,857 Added 179.98%	34,001 $1.03 Million
Q4 2020 Feb 11, 2021	SELL	$37.86 - $54.26 $1.38 Million - $1.98 Million	-36,411 Reduced 74.99%	12,144 $602,000
Q3 2020 Nov 12, 2020	SELL	$35.13 - $43.62 $121,163 - $150,445	-3,449 Reduced 6.63%	48,555 $1.87 Million
Q2 2020 Aug 12, 2020	BUY	$23.66 - $49.53 $975,336 - $2.04 Million	41,223 Added 382.37%	52,004 $2.25 Million
Q1 2020 May 13, 2020	SELL	$14.39 - $35.8 $248,673 - $618,659	-17,281 Reduced 61.58%	10,781 $281,000
Q4 2019 Feb 10, 2020	BUY	$23.81 - $33.78 $365,745 - $518,894	15,361 Added 120.94%	28,062 $878,000
Q3 2019 Nov 14, 2019	SELL	$21.57 - $31.37 $9,016 - $13,112	-418 Reduced 3.19%	12,701 $331,000
Q2 2019 Aug 14, 2019	SELL	$19.51 - $28.31 $61,124 - $88,695	-3,133 Reduced 19.28%	13,119 $300,000
Q1 2019 May 15, 2019	BUY	$18.21 - $26.21 $107,675 - $154,979	5,913 Added 57.19%	16,252 $426,000
Q4 2018 Feb 14, 2019	BUY	$15.41 - $28.92 $159,323 - $299,003	10,339 New	10,339 $210,000

Others Institutions Holding YMAB

# of Institutions

Shares Held

22.4M

Call Options Held

37.4K

Put Options Held

48.2K

View Full List

About Y-mAbs Therapeutics, Inc.

Ticker YMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,719,500
Market Cap $529M
Description
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...

More about YMAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account